Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1996 • 2,073 citations

Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells

2001 • 1,384 citations

CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection

1994 • 1,161 citations

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

1999 • 1,131 citations

High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190

2000 • 923 citations

T CELL MEMORY

1998 • 863 citations

Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines

1994 • 841 citations

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1

1999 • 803 citations

Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells

1989 • 706 citations

Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex.

1991 • 628 citations

Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.

1995 • 552 citations

HLA-A2.1-Associated Peptides from a Mutant Cell Line: A Second Pathway of Antigen Presentation

1992 • 522 citations

An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.

1996 • 416 citations

Cytokine production, serum levels and disease activity in systemic lupus erythematosus.

2000 • 285 citations

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptidesin vivo: Implications for tumor vaccines with melanoma-associated antigens

1996 • 250 citations

Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses.

1992 • 224 citations

Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.

1994 • 181 citations

Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-γ gene and protein expression in lupus T cells

2001 • 179 citations

Terminal modifications inhibit proteolytic degradation of an immunogenic mart-127-35 peptide: Implications for peptide vaccines

1999 • 166 citations

Structural and Immunological Characterization of the Vaccine Adjuvant QS-21

1995 • 139 citations

Delineation of several DR-restricted tetanus toxin T cell epitopes.

1989 • 136 citations

Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells

1998 • 129 citations

Identification of a novel peptide derived from the melanocyte‐specific gp100 antigen as the dominant epitope recognized by an HLA‐A2.1‐restricted anti‐melanoma CTL line

1995 • 128 citations

T cell memory. Long-term persistence of virus-specific cytotoxic T cells.

1989 • 109 citations

Evaluation of CD8+ T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide

2000 • 107 citations

Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.

1996 • 106 citations

Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.

1999 • 98 citations

Localization of HLA-A2.1-restricted T cell epitopes in the circumsporozoite protein of Plasmodium falciparum.

1995 • 69 citations

Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations

1997 • 62 citations

Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex

2000 • 52 citations

Interleukin‐10 blockade corrects impaired in vitro cellular immune responses of systemic lupus erythematosus patients

2000 • 51 citations

HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients

1999 • 48 citations

Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer Antigen Processing and Presentation Autologous Human Dendriphages Pulsed with Synthetic or Natural Tumor Peptides Elicit Tumor-Specific CTLs In Vitro

1998 • 44 citations

Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations.

2001 • 42 citations

Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice

1999 • 24 citations

Toxicity of adjuvant high-dose interferon-alpha-2b in patients with cutaneous melanoma at high risk of recurrence.

1999 • 19 citations

[Pilot study of interferon alpha-2b tolerance in patients with stage III melanoma].

1999 • 1 citations